Merck Announces Data For V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed For Adults

Merck & Co., Inc. -2.09% Pre

Merck & Co., Inc.

MRK

125.44

125.44

-2.09%

0.00% Pre

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases

Results build on the data supporting the clinical profile of V116 for adults

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via